

DAFTAR PUSTAKA

- Adelsberger, H., Quasthoff, S., Grosskreutz, J., Lepier, A., Eckel, F. and Lersch, C. 2000. The chemotherapeutic oxaliplatin alters voltage-gated Na (+) channel kinetics on rat sensory neurons, *European Journal of Pharmacology Eur J Pharmacol*406 (1):25–32.
- Aloe, L, Rocco, M.L., Bianchi, P. and Manni, L. 2012. Nerve growth factor: from the early discoveries to the potential clinical use, *Journal of Translational Medicine J Transl Med*10 (1).
- Aromolaran, K.A., Goldstein, P.A. 2017. 'Ion Channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy', *Molecular Pain*, 13, p. 174480691771469.
- Azhary H, Farooq MU, Bhanushali M, Majid A, Kassab MY. Peripheral neuropathy: differential diagnosis and management. *Am Fam Physician*. 2010 Apr 1;81(7):887-92. PMID: 20353146.
- Bailly, C. 2019. 'Irinotecan: 25 years of cancer treatment', *Pharmacological Research*, 148, p. 104398.
- Balducci, L. and Extermann, M., 2000. Management of cancer in the older person: a practical approach., *The Oncologist England*5 (3):224–237.
- Bardal, S.K., Waechter, J.E. and Martin, D.S. 2011. 'Neoplasia', *Applied Pharmacology*, pp. 305–324.
- Barker, P.A. *et al.* 2020. 'nerve growth factor signaling and its contribution to pain', *Journal of Pain Research*, Volume 13, pp. 1223–1241.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. 2020. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, *CA: A Cancer Journal for Clinicians Wiley*68 (6):394–424.
- Buiet, G., Delvigne, V., le Dantec, G., Guyonnet-Debersac, P. and Taïeb, C. 2022. Prevalence of radiotherapy, chemotherapy and access to supportive care in cancer in Brazil, China, France, Russia and the USA, *European Journal of Cancer Care Eur J Cancer Care (Engl)*31 (6).
- Burgess, J. *et al.* 2021. 'Chemotherapy-induced peripheral neuropathy: Epidemiology, Pathomechanisms and treatment', *Oncology and Therapy*, 9(2), pp. 385–450.
- Caley, A. and Jones, R. 2012. 'The principles of cancer treatment by chemotherapy', *Surgery (Oxford)*, 30(4), pp. 186–190.

- Castelli, G., Desai, K.M. and Cantone, R.E. 2020. Peripheral Neuropathy: Evaluation and Differential Diagnosis, *American Family Physician* 102 (12):732–739.
- Cavaletti, G., Bogliun, G., Marzorati, L., *et al.* 2004. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy, *Annals of Oncology : Official Journal of the European Society for Medical Oncology* Ann Oncol15 (9):1439–1442.
- Chang, D.S., Hsu, E., Hottinger, D.G. and Cohen, S.P. 2016. Anti-nerve growth factor in pain management: current evidence, *Journal of Pain Research J Pain Res*9373–383.
- Cheng, H.L. and Molassiotis, A. 2018. ‘Longitudinal validation and comparison of the Chinese version of the European Organization for research and treatment of cancer quality of life-chemotherapy-induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of cancer-Gynecologic Oncology group-neurotoxicity Subscale (fact/gog-ntx)’, *Asia-Pacific Journal of Clinical Oncology*, 15(1), pp. 56–62.
- Chitimus, D.M., Jurcuț, C. and Pleșa, C.-F. 2021 ‘Peripheral neuropathy: A practical guide for internists’, *Internal Medicine*, 18(5), pp. 53–62. doi:10.2478/inmed-2021-0182.
- Chung, K.H. *et al.* 2022. ‘Mechanisms, mediators, and moderators of the effects of exercise on chemotherapy-induced peripheral neuropathy’, *Cancers*, 14(5), p. 1224.
- Colvin M. 2003. Alkylating Agents. In: Kufe DW, Pollock RE, Weichselbaum RR, *et al.*, editors. *Holland-Frei Cancer Medicine*. 6th edition. Hamilton (ON): BC Decker; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK12772/>
- Debela, D.T. *et al.* 2021. ‘New approaches and procedures for cancer treatment: Current perspectives’, *SAGE Open Medicine*, 9, p. 205031212110343.
- Derissen, E.J. and Beijnen, J.H. 2020. ‘Intracellular pharmacokinetics of pyrimidine analogues used in oncology and the correlation with drug action’, *Clinical Pharmacokinetics*, 59(12), pp. 1521–1550.
- Desforges, A.D. *et al.* 2022. ‘Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: An update’, *Biomedicine & Pharmacotherapy*, 147, p. 112671.
- De Santis, S., Pace, A., Bove, L., *et al.* 2000. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor., *Clinical Cancer Research : An Official Journal of the American Association for Cancer Research United States*6 (1):90–95.

- Dorand, R.D., Zheng, N.S., Agarwal, R., et al., 2023. Correlates of Taxane-Induced Neuropathy, an Electronic Health Record Based Observational Study, *Cancers* 15 (3).
- Dyba, T., Randi, G., Bray, F., et al. 2021. The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers, *European Journal of Cancer* Elsevier 157308.
- Felson, S., 2022. Cancer Incidence Rates by Age, *WebMD*, available at: <https://www.webmd.com/cancer/cancer-incidence-age> (accessed 26 November 2024).
- Firdaus, N.Z. and Susilowati, S., 2023. Evaluasi Penggunaan Kemoterapi pada Pasien Kanker Payudara di Rumah Sakit Islam Sultan Agung Semarang Tahun 2022, *Jurnal Ilmu Farmasi Dan Farmasi Klinik* 20 (2):155.
- Freeman, M.R. 2014. ‘Signaling mechanisms regulating Wallerian degeneration’, *Current Opinion in Neurobiology*, 27, pp. 224–231.
- Flatters, S.J.L., Dougherty, P.M. and Colvin, L.A. 2017. ‘Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): A narrative review’, *British Journal of Anaesthesia*, 119(4), pp. 737–749.
- García-Domínguez, M. 2025. NGF in Neuropathic Pain: Understanding Its Role and Therapeutic Opportunities. *Current Issues in Molecular Biology*, 47(2), 93.
- Ghazisaeidi, S., Muley, M.M. and Salter, M.W., 2023. Neuropathic Pain: Mechanisms, Sex Differences, and Potential Therapies for a Global Problem, *Annual Review of Pharmacology and Toxicology* 63565–583.
- Greenlee, H., Hershman, D.L., Shi, Z., et al., 2017. BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study., *Journal of the National Cancer Institute* United States 109 (2).
- Grigorescu, A.C. 2015. Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest, *Journal of Translational Internal Medicine* J Transl Int Med 3 (1):24–28.
- Guastalla, J.P. and Diéras, V., 2003. The taxanes: Toxicity and quality of life considerations in advanced ovarian cancer, *British Journal of Cancer* 89 (SUPPL. 3):16–22.
- Halter, J., Ouslander J, T.M. et al. 2009. Hazzard’s Geriatric Medicine and Gerontology, 6e AccessMedicine McGraw Hill Medical, New York: *The McGraw-Hill Companies*, available at : <https://accessmedicine.mhmedical.com/content.aspx?bookid=3201§ionid=266642315> (accessed 5 May 2023).

- Hammi, C. and Yeung, B. 2022. *Neuropathy* StatPearls [Internet], available at: <https://www.ncbi.nlm.nih.gov/books/NBK542220/>.
- Hanewinkel, R., Ikram, M.A. and Van Doorn, P.A. 2016. 'Peripheral neuropathies', *Neuroepidemiology*, pp. 263–282.
- Hendrayana, T., Wilmer, A., Kurth, V., Schmidt-Wolf, I.G.H. and Jaehde, U. 2017. Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application, *Scientia Pharmaceutica Sci Pharm* 85 (1).
- Huang, J., Ngai, C.H., Deng, Y., *et al.* 2022. Cancer Incidence and Mortality in Asian Countries: A Trend Analysis, *Cancer Control: Journal of the Moffitt Cancer Center* SAGE Publications 291–11.
- Hu, L.-Y. *et al.* 2019. 'Prevention and treatment for chemotherapy-induced peripheral neuropathy: Therapies based on CIPN Mechanisms', *Current Neuropharmacology*, 17(2), pp. 184–196.
- Imai, S., Koyanagi, M., Azimi, Z., *et al.*, 2017. Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms, *Scientific Reports* 7 (1):5947.
- Infante Lara, L. *et al.* 2018. 'Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences', *Nucleic Acids Research*, 46(5), pp. 2218–2233.
- Information, N.C. for B. 2019. National Center for Biotechnology Information. PubChem compound database paclitaxel., available at: <https://pubchem.ncbi.nlm.nih.gov/compound/36314>. (accessed 5 May 2023).
- Information, N.C. for B. 2019. National Center for Biotechnology Information. PubChem compound database carboplatin, available at: <https://pubchem.ncbi.nlm.nih.gov/compound/38904>. (accessed 5 May 2023).
- Jemal, A., Ward, E.M., Johnson, C.J., *et al.* 2019. Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival, *Journal of the National Cancer Institute* Oxford University Press 109 (9).
- Kemenkes RI, 2018. PROFIL KESEHATAN INDONESIA TAHUN. 2020.
- Khalefa, H.G. *et al.* 2020 'Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: A randomized controlled study', *Breast Cancer Research and Treatment*, 183(1), pp. 117–125.

- Kim, J. and Hurria, A. 2013. Determining Chemotherapy Tolerance in Older Patients With Cancer, *Journal of the National Comprehensive Cancer Network : JNCCN* NIH Public Access11 (12):1494.
- Khan, N. and Smith, M. 2015. ‘Neurotrophins and neuropathic pain: Role in Pathobiology’, *Molecules*, 20(6), pp. 10657–10688.
- Klafke, N. *et al.* 2023. ‘Prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN) with non-pharmacological interventions: Clinical recommendations from a systematic scoping review and an expert consensus process’, *Medical Sciences*, 11(1), p. 15.
- Lang, U.E. *et al.* (2003) ‘Nerve growth factor serum concentrations in healthy human volunteers: Physiological variance and stability’, *Neuroscience Letters*, 344(1), pp. 13–16.
- Launay-Vacher, V., Janus, N. and Deray, G. 2016. Renal insufficiency and cancer treatments, *ESMO Open* ESMO Open1 (4).
- Lauria, G., Hsieh, S.T., Johansson, O., *et al.* 2010. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society, *European Journal of Neurology* Eur J Neurol17 (7):903-e49.
- Lewin, G.R. and Barde, Y.A. 1996. Physiology of the neurotrophins, *Annual Review of Neuroscience* Annu Rev Neurosci19289–317.
- Lehmann, F. and Wennerberg, J. 2021. ‘Evolution of nitrogen-based alkylating anticancer agents’, *Processes*, 9(2), p. 377.
- Lehmann, H.C., Wunderlich, G., Fink, G.R. and Sommer, C., 2020. Diagnosis of peripheral neuropathy., *Neurological Research and Practice* England220.
- Lichtman, S.M., Wildiers, H., Chatelut, E., *et al.* 2007. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature, *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology* J Clin Oncol25 (14):1832–1843.
- Lind, M.J. 2016. ‘Principles of Systemic Anticancer Therapy’, *Medicine*, 44(1), pp. 20–24.
- Lixian, S., Xiaoqian, Y., Luyan, G., *et al.*, 2024. Risk factors of paclitaxel-induced peripheral neuropathy in patients with breast cancer: a prospective cohort study, *Frontiers in Oncology* 14 (March):1–11.

- Maldonado, F. 2023. *Nitrosourea-induced pulmonary injury*, *UpToDate*. Available at: <https://www.uptodate.com/contents/nitrosourea-induced-pulmonary-injury#> (Accessed: 05 September 2023).
- Mallo, A.R., Manginstar, C., Merung, M.A. and Langi, F.E.L.F.G.O., 2024. Respon Klinis Regimen Kemoterapi pada Kanker Payudara Stadium Lanjut di RSUP Prof. Dr. R.D. Kondou Manado tahun 2023, *Jurnal Sosial Dan Sains* 41045–1057.
- Maihöfner, C. *et al.* 2021. ‘Chemotherapy-induced peripheral neuropathy (CIPN): Current therapies and topical treatment option with high-concentration capsaicin’, *Supportive Care in Cancer*, 29(8), pp. 4223–4238.
- Meng, J. *et al.* 2019. ‘Duloxetine, a balanced serotonin-norepinephrine reuptake inhibitor, improves painful chemotherapy-induced peripheral neuropathy by inhibiting activation of p38 MAPK and NF-KB’, *Frontiers in Pharmacology*, 10.
- Montagnoli, C., Tiribuzi, R., Crispoltoni, L., *et al.*, 2017. β -NGF and β -NGF receptor upregulation in blood and synovial fluid in osteoarthritis., *Biological Chemistry Germany* 398 (9):1045–1054.
- Muthalib, A. 2007. Prinsip dasar terapi sistemik pada kanker., in Sudoyo, A., Setiyohadi, B., Alwi, I., Simadibrata, M. and Setiati, S. (Eds.), *Buku Ajar Ilmu Penyakit Dalam*. Balai Penerbit FKUI, Jakarta pp. 2882–3.
- National Cancer Institute. 2022. What Is Cancer? - NCI, *What Is Cancer?*, available at: <https://www.cancer.gov/about-cancer/understanding/what-is-cancer> (accessed 4 May 2023).
- National Comprehensive Cancer Network. 2018. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: older adult oncology, available at: [NCCN.org](https://www.nccn.org).
- NCBI. 2019. National Center for Biotechnology Information. PubChem compound database dacarbazine, available at: <https://pubchem.ncbi.nlm.nih.gov/compound/135398738> (accessed 5 May 2023).
- NCI. 2021. Cancer Statistics - NCI, *Cancer Statistics*, available at: <https://www.cancer.gov/about-cancer/understanding/statistics> (accessed 11 April 2023).
- Niewiadomska, G., Mietelska-Porowska, A. and Mazurkiewicz, M. 2011. ‘The cholinergic system, nerve growth factor and the cytoskeleton’, *Behavioural Brain Research*, 221(2), pp. 515–526.

- Novriansyah, A. 2014, Uji diagnostik Toronto Clinical Scoring System terhadap diagnosis neuropati perifer terinduksi kemoterapi, available at: <https://lontar.ui.ac.id/detail?id=20367194&lokasi=lokal> (accessed 12 November 2023)
- Nyambe, H., 2022. Perbandingan Kesintasan Pasien Kanker Paru Kelompok Bukan Sel Kecil Yang Mendapat Terapi Target Epidermal Growth Factor Receptor-Tyrosin Kinase Inhibitor Dan Yang Mendapat Kemoterapi Lini Pertama Universitas Hasanuddin.
- Petrovchich, I., Kober, K.M., Wagner, L., et al., 2019. Deleterious Effects of Higher Body Mass Index on Subjective and Objective Measures of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors., *Journal of Pain and Symptom Management* United States 58 (2):252–263.
- Raimondi, M. et al. 2019. ‘DHFR inhibitors: Reading the past for discovering novel Anticancer Agents’, *Molecules*, 24(6), p. 1140.
- Rattanakrong, N. et al. 2022. ‘Reliability and validity of the EORTC QLQ-CIPN20 (European Organization for research and treatment of cancer quality of life questionnaire–chemotherapy-induced peripheral neuropathy 20-item scale) among Thai women with breast cancer undergoing Taxane-based chemotherapy’, *Asian Pacific Journal of Cancer Prevention*, 23(5), pp. 1547–1553
- Riaz, S.S. and Tomlinson, D.R. 1996. Neurotrophic factors in peripheral neuropathies: pharmacological strategies, *Progress in Neurobiology* Prog Neurobiol 49 (2):125–143.
- Rodwin, R.L. et al. 2022. ‘Biomarkers of chemotherapy-induced peripheral neuropathy: Current status and Future Directions’, *Frontiers in Pain Research*, 3.
- Saif, M. and Chu, E. 2011. Antimetabolites, in Hellman, D. and Rosenberg (Eds.), *Cancer : Principles & Practice of Oncology*, 10th ed. Wolters Kluwer Health, USAp. 371.
- Salas, S., Mercier, S., Moheng, B., et al. 2017. Nutritional status and quality of life of cancer patients needing exclusive chemotherapy: a longitudinal study, *Health and Quality of Life Outcomes* Health Qual Life Outcomes 15 (1).
- Salat, K. 2020. ‘Chemotherapy-induced peripheral neuropathy: Part 1—current state of knowledge and perspectives for pharmacotherapy’, *Pharmacological Reports*, 72(3), pp. 486–507.

- Sanford, D., Goedegebuure, S. and Eberlein, T. 2012. Tumor biology and tumor marker., *Sabiston Textbook of Surgery.*, 19th ed. Elsevier, Philadelphia. 683.
- Savić, D. *et al.* 2015. ‘Purine nucleoside analogs in the therapy of cancer and Neuroinflammation’, *Molecular inhibitors in targeted therapy*, 1(1).
- Seretny, M., Currie, G.L., Sena, E.S., *et al.* 2014. Comprehensive review 4 Incidence, prevalence, and predictors of chemotherapy-induced 5 peripheral neuropathy: A systematic review and meta-analysis 6 7 8, *Chemotherapy Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis*, *Pain* 155 (12):2461–2470.
- Simão, D.A. *et al.* 2015 ‘Chemotherapy-induced peripheral neuropathy: Review for clinical practice’, *Revista Dor*, 16(3).
- Sisignano, M., Lötsch, J., Parnham, M.J. and Geisslinger, G., 2019. Potential biomarkers for persistent and neuropathic pain therapy, *Pharmacology & Therapeutics* 199:16–29.
- Skaper, S.D. 2017. Nerve growth factor: a neuroimmune crosstalk mediator for all seasons, *Immunology* Wiley-Blackwell 151 (1):1.
- Soejitno, A. and Widyadharma, I.P. (2024) ‘Chemotherapy-induced peripheral neuropathy biomarkers: Current updates, challenges, and potentials’, *The Egyptian Journal of Neurology, Psychiatry and Neurosurgery*, 60(1).
- Sreeram, K., Seaton, R., Greenwald, M.K., *et al.*, 2023. Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort., *Cancer Causes & Control : CCC* Netherlands 34 (5):459–468.
- Staff, N.P., Grisold, A., Grisold, W. and Windebank, A.J., 2017. Chemotherapy-induced peripheral neuropathy: A current review, *Annals of Neurology* Ann Neurol 81 (6):772–781.
- Starobova, H. and Vetter, I. 2017. ‘Pathophysiology of chemotherapy-induced peripheral neuropathy’, *Frontiers in Molecular Neuroscience*, 10.
- Tanay, M.A.L., Armes, J. and Ream, E. 2016. ‘The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: A qualitative thematic synthesis’, *European Journal of Cancer Care*, 26(5).
- U.S. Food and Drug Administration, 2017. *new drug therapy approvals* . Available at: <https://www.fda.gov/media/110526/download> (Accessed: 12 August 2023).

- Velasco, R. *et al.* 2013. 'Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients', *Journal of Neurology, Neurosurgery & Psychiatry*, 85(4), pp. 392–398.
- Velasco, R., Navarro, X., Gil-Gil, M., Herrando-Grabulosa, M., Calls, A., and Bruna, J. 2017. Neuropathic Pain and Nerve Growth Factor in Chemotherapy-Induced Peripheral Neuropathy: Prospective Clinical-Pathological Study, *Journal of Pain and Symptom Management* 54 (6):815–825.
- Wang, J.T., Medress, Z.A. and Barres, B.A. 2012. 'Axon degeneration: Molecular mechanisms of a self-destruction pathway', *Journal of Cell Biology*, 196(1), pp. 7–18.
- Xu, H., Xu, L., Page, J.H., *et al.* 2016. Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010-2013, *Clinical Epidemiology Clin Epidemiol* 861–71.
- Wong, M.L., Cooper, B.A., Paul, S.M., *et al.*, 2019. Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors., *Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer* 27 (10):3905–3912.
- Youk, J., Kim, Y.-S., Lim, J.-A., *et al.*, 2017. Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies., *PloS One* United States 12 (8):e0183491.
- Yuen, E.C., Howe, C.L., Li, Y., Holtzman, D.M. and Mobley, W.C. 1996. Nerve growth factor and the neurotrophic factor hypothesis, *Brain and Development* Elsevier B.V. 18 (5):362–368.
- Zhang, S. 2021. Chemotherapy-induced peripheral neuropathy and rehabilitation: A review, *Seminars in Oncology* W.B. Saunders 48 (3):193–207.
- Zajączkowska, R. *et al.* 2019 'Mechanisms of chemotherapy-induced peripheral neuropathy', *International Journal of Molecular Sciences*, 20(6), p. 1451.